Dr. Vogel to Lead Joint Breast Cancer Program

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 3
Volume 5
Issue 3

PITTSBURGH--Victor Vogel, MD, MHS, will lead a newly established joint breast cancer program of the University of Pittsburgh Cancer Institute and Magee-Womens Hospital. He will also join the University of Pittsburgh as professor of medicine and epidemiology.

PITTSBURGH--Victor Vogel, MD, MHS, will lead a newly establishedjoint breast cancer program of the University of Pittsburgh CancerInstitute and Magee-Womens Hospital. He will also join the Universityof Pittsburgh as professor of medicine and epidemiology.

Dr. Vogel comes to Pittsburgh from the University of Texas M.D.Anderson Cancer Center, where he was responsible for recruitingthe largest number of women onto the Breast Cancer PreventionTrial, the national study designed to determine the value of tamoxifen(Nolva-dex) in preventing breast cancer in high-risk women.

"One of the program's most important missions," Dr.Vogel said, "will be to enhance delivery of care to womenwho face barriers, ie, older women or those who are poor or livein rural areas."

Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.